ARS Pharmaceuticals Reports Health Canada Approval of Neffy 2mg to Treat Type I Allergic Reactions
Health Canada has approved ARS Pharma’s neffy 2 mg adrenaline nasal spray for adults and children weighing over 30 kg, marking the first needle‑free emergency treatment for anaphylaxis in the country. In November 2024, ARS granted ALK exclusive rights to commercialize neffy outside the United States, securing a $155 million upfront payment and up to $310 million in regulatory and sales milestones, plus tiered double‑digit royalties. ARS will supply the product to ALK for a Canadian launch slated for summer 2026, while a 1 mg version for children 15‑30 kg is slated for a Health Canada filing this summer. Joint filings with Pediatrix Therapeutics aim to introduce the 1 mg dose in China in the coming months.
MRNA Nanoparticles Teach Beta Cells to Prevent Type 1 Diabetes
As a medical school professor, I can tell you: what we've been doing for type 1 diabetes is managing, not curing. University of Chicago scientists just changed the game. They developed mRNA-loaded nanoparticles that deliver genetic instructions directly to insulin-producing beta cells,...
Will Cancer Drugmakers Ever Conquer P53?
Elephants’ 20 copies of the TP53 gene give them a powerful p53‑driven cancer shield, while humans rely on a single copy that is frequently mutated. Restoring p53 function has long been labeled “undruggable,” leading to a string of high‑profile failures,...
Today's Teen Could Become First 150‑year‑old
David Sinclair says the first person to live to 150 is a teenager who's alive today. He's taken flak from colleagues for years over this prediction. He doesn't care. He still stands by it. "The first person to live to 150 has...
Takeda Continues to Prune Partnerships, Cuts Ties with mRNA-Targeting Veritas In Silico
Takeda announced the termination of its three‑year partnership with Veritas In Silico, a collaboration focused on small‑molecule drugs that target mRNA. The split, confirmed on April 13, follows a recent wave of collaborator cuts, including a break with Denali Therapeutics and...
TOBY Secures US FDA Breakthrough Device Designation for Urine-Based Multi-Cancer Test
TOBY has received FDA Breakthrough Device Designation for its urine‑based Multi‑Cancer Early Detection (MCED) test. The non‑invasive platform analyzes volatile organic compounds in a single urine sample using spectroscopy and machine‑learning algorithms to identify multiple cancer types. The designation positions...
Enhancing Oxidase‐Catalyzed Biosensing via Hydrophobic ZIF‐7 Nanomaterials: A Micro‐Triphase Interface Approach
The study introduces ZIF-7 nanoparticles as hydrophobic oxygen reservoirs in a solid–liquid–air triphase enzyme electrode, boosting oxidase‑catalyzed biosensing. By releasing pre‑stored O₂, the system raises Vmax 21‑fold and widens the glucose linear range from 2 mM to 20 mM, a ten‑fold improvement...
Bioadhesive Scaffold for Dual Delivery of Methotrexate‐Loaded Liposomes and Chondrogenic miRNA in Advanced Rheumatoid Arthritis Therapy
Researchers have engineered a bioadhesive scaffold that couples inflammation‑responsive methotrexate‑loaded liposomes with miRNA‑140‑bearing nanoparticles to treat advanced rheumatoid arthritis. The scaffold, composed of collagen, polydopamine‑modified hyaluronic acid and PEGDE cross‑linker, adheres to joint tissue, releases methotrexate when matrix metalloproteinases are...
Tumor Microenvironment‐Responsive Dual‐Enzymatic Flasklike Nanobots for Enhanced Chemotherapy
Researchers have engineered a flask‑shaped nanobot (GC‑M@FPNbot) that harnesses glucose oxidase and catalase to self‑propel in response to tumor‑specific proton and hydrogen peroxide gradients. Loaded with doxorubicin, the bots exhibit chemotactic motion that enables deep penetration of extracellular matrix and...
Multimodal Analysis of the Early Stage of Amyloid Formation via Graphene Liquid Cell Electron Microscopy
Researchers have combined graphene liquid‑cell transmission electron microscopy (GLC‑TEM) with semi‑ensemble and time‑sequential analyses to watch amyloid‑β oligomer formation in real time. The multimodal approach reveals that early‑stage aggregates exist in a kinetic quasi‑equilibrium, where rapid association‑dissociation events keep population...
Atelerix Forms Strategic Partnership With JH Health Ltd to Expand Non-Cryogenic Cell Preservation Capabilities in the Middle East
Atelerix, a UK biotech, has signed a strategic partnership with Saudi Arabia’s JH Health Ltd, granting JH Health exclusive rights to distribute Atelerix’s non‑cryogenic hydrogel cell‑preservation solutions across the Middle East. The deal includes funding for high‑volume local manufacturing, regulatory...
Navigated TMS Cuts Combat PTSD Symptoms for 85% in Landmark Trial
Researchers at UT Health San Antonio reported that a patented, MRI‑guided, robotic transcranial magnetic stimulation (TMS) protocol reduced PTSD symptoms in 85% of combat‑exposed service members and veterans when combined with intensive psychotherapy. The randomized trial, published in JAMA Network...
STAT+: New Bain Biotech Startup, Building on BMS Drugs, Gets a Name and a CEO
Bain Capital Life Sciences has launched a new biotech venture, Beeline Medicines, backed by a $300 million investment and five drug assets licensed from Bristol Myers Squibb. The startup will focus on inflammatory and immune‑mediated diseases, beginning with an oral candidate for...
Danish MinervaX Bolsters Executive Team Amid Transition to Pivotal Vaccine Trial Phase
Denmark‑based biotech MinervaX has hired Jamila Louahed, a former GSK vaccine R&D executive, as Chief Development Officer and veteran life‑science CFO Hans Henrik Chrois Christensen. The leadership changes come as the company prepares to launch a pivotal Phase III trial...
Beetroot Nitrate Supplement Raises Nitric Oxide Markers in Amateur Triathletes After One Week
Researchers in Italy found that a beetroot‑derived nitrate supplement significantly elevated nitric‑oxide and redox biomarkers in amateur triathletes after just one week of daily use. The open‑label crossover study reported no adverse effects, though performance outcomes were not measured, highlighting...
Texas A&M Nasal Spray Reverses Brain Aging in Preclinical Study
Researchers at Texas A&M University, led by Dr. Ashok Shetty, showed that a two‑dose extracellular‑vesicle nasal spray eliminated neuroinflammation and restored memory in aged rodents. The preclinical results, published in the Journal of Extracellular Vesicles, suggest a non‑invasive route to...
FDA Grants Priority Review to Daiichi Sankyo, Merck’s B7‑H3 ADC for Small‑Cell Lung Cancer
The U.S. Food and Drug Administration has placed Daiichi Sankyo and Merck’s ifinatamab deruxtecan (I‑DXd) on its Priority Review list for extensive‑stage small‑cell lung cancer (ES‑SCLC) that progressed after platinum chemotherapy. The agency set an October 10 2026 decision deadline and will...
QIAGEN Launches QIAstat-Dx BCID GPF Plus AMR Panel for Bloodstream Infection Syndromic Testing
QIAGEN has launched the CE‑IVDR‑certified QIAstat‑Dx BCID GPF Plus AMR Panel for rapid bloodstream‑infection syndromic testing. The assay detects 20 gram‑positive bacterial and fungal targets and ten antimicrobial‑resistance markers, delivering results in approximately one hour. Announced at the ESCMID Global...
AWS Unveils Amazon Bio Discovery AI Platform to Accelerate Early‑Stage Drug Development
Amazon Web Services launched Amazon Bio Discovery, an AI‑powered application that lets researchers run complex drug‑discovery workflows without coding. Early adopters include Bayer, the Broad Institute and Memorial Sloan Kettering, and the tool promises to shrink antibody‑design cycles from months...
J&J Targets $100B Revenue, Replimune Rebuffed Again and a “Revolution” In Pancreatic Cancer
Johnson & Johnson reported $24.1 billion in first‑quarter sales and set an ambitious $100 billion revenue target for 2026, underscoring its aggressive growth strategy amid a wave of biotech M&A. Replimune’s advanced melanoma therapy RP1 was denied again, with the FDA insisting...
Cellular Senescence and Mitochondrial Dysfunction and the Aging of the Vascular Endothelium
The review links cellular senescence and mitochondrial dysfunction to the aging of the vascular endothelium, showing how reduced nitric‑oxide, oxidative stress, and chronic inflammation drive atherosclerosis, hypertension, and blood‑brain barrier leakage. It details a feedback loop where mitochondrial bioenergetic decline...
Homoharringtonine as a Senotherapeutic Drug
Researchers used a large‑scale drug‑repositioning screen to identify homoharringtonine (HHT), an FDA‑approved anti‑leukemic agent, as a potent senotherapeutic. In vitro, HHT selectively eliminated senescent pre‑adipocytes while sparing healthy cells. In male mice, HHT cleared senescent adipocytes, restored white‑adipose tissue function,...
Nanoz Unveils 2 Mm AI‑Powered Nanosensors for Health Diagnostics and Pollution Tracking
Nanoz, a French deep‑tech firm, launched 2‑mm AI‑powered nanosensors that identify complex gas signatures for medical diagnostics and environmental monitoring. The devices, built on metal‑oxide semiconductor technology, aim to bring non‑invasive breath tests and real‑time air‑quality data to markets worldwide.
SynuSight’s Α‑syn PET Tracer SST001 Cleared by China’s NMPA for Phase I Trial
Mabwell’s incubated unit SynuSight Biotech announced that the National Medical Products Administration approved its α‑synuclein PET tracer SST001 for a Phase I trial in China. The non‑randomized study will enroll healthy volunteers, Parkinson’s disease and multiple system atrophy patients at...
How Are Regulatory Factors Impacting Biosimilars
The FDA issued draft guidance in March that would drop certain pharmacokinetic (PK) studies for biosimilars, aiming to lower development costs. At the same time, the Inflation Reduction Act (IRA) and most‑favored‑nation (MFN) pricing provisions are reshaping how manufacturers price...
Why Genetic Diagnoses Take So Long for Kids
In this brief episode, host Catherine interviews the CEO of GeneDX about the stark delay—averaging five years—in diagnosing children with genetic diseases, despite the availability of rapid whole exome and genome sequencing that can deliver results in days. She explains...
AllogeneTx Stock Plummets After $2 Share Offering
I saw that a lot of people on 𝕏 are surprised by the sharp decline in $ALLO stock price - from $4.3 to $2.2 in one day despite the company’s excellent cema-cel readout 🧵👇. The reason for this decline is...
GlycoNex Secures Japan’s PMDA Approval for GNX1021 Phase I Trial
GlycoNex has secured approval from Japan’s Pharmaceuticals and Medical Devices Agency to launch a first‑in‑human Phase I study of its lead ADC, GNX1021, in advanced gastrointestinal cancers. The multi‑centre trial will begin patient enrollment in Japan by June 2026, with parallel IND...
Blood Test Predicts Kidney Failure Risk to Black Americans Years Before Onset
University of Pennsylvania researchers have unveiled a blood‑based test that predicts kidney‑failure risk in individuals of African ancestry carrying high‑risk APOL1 gene variants. The assay measures a small panel of circulating proteins to generate a ten‑year risk score, distinguishing patients...
A Molecular Movie Captures Cancer's Great Escape From Targeted Therapy
Researchers at the Institute for Systems Biology captured a "molecular movie" showing that melanoma cells enter a reversible, drug‑tolerant state within hours of BRAF‑targeted therapy. The study, published in Nature Communications, reveals an ordered two‑wave transcriptional program driven by NF‑κB‑mediated...
Scientists Turn AI-Generated Proteins Into Smart Molecular Sensors
An international team led by Queensland University of Technology used artificial intelligence to engineer tiny "smart" proteins that activate only when they bind a chosen molecule. Published in Nature Biotechnology, the AI‑designed switches produce color, light or electrical outputs, and...
No One’s Sure if Synthetic Mirror Life Will Kill Us All
In 2019 a group of synthetic biologists and ethicists convened to explore funding for “mirror” bacteria—microbes built from opposite‑handed proteins, sugars and lipids. By 2024, many participants warned that such organisms could evade natural predators and immune systems, potentially causing...
Can Europe Finance and Keep Its Biotech Winners?
The United States saw a surge of life‑sciences IPOs in early 2026, raising over $1 billion, while Europe continues to lose its biotech firms to foreign markets. Over the past six years, 66 of 67 EU biotech companies that went public...
Mending University and Venture Capital Relations: Is It Possible to See Eye-to-Eye?
European university spin‑outs in deep‑tech and life sciences now represent a $398 billion asset pool, but collaboration with venture capitalists remains fraught. Tech transfer offices are tasked with bridging divergent goals—academia’s focus on discovery and publications versus VCs’ demand for speed...
Partner Therapeutics Reports the US FDA sBLA Submission of Bizengri for NRG1 Fusion Positive Cholangiocarcinoma
Partner Therapeutics has filed a supplemental Biologics License Application (sBLA) with the U.S. FDA for Bizengri (zenocutuzumab‑zbco), a monoclonal antibody designed for adults with advanced unresectable or metastatic cholangiocarcinoma that carry an NRG1 gene fusion. The filing is supported by...
Robotic Phlebotomy Achieves 94% Success, Low Complications
I've been following Vitestro for years. They have been developing robotic devices to collect patients' blood samples. They have big news now as the results of a multicenter ADOPT clinical trial have been published in Clinical Chemistry. That is the...
Toast-Time Trade-Off Eases as Gene-Edited Wheat Cuts Acrylamide Risk by 93%
Scientists at Rothamsted Research used CRISPR to edit wheat genes, slashing free asparagine levels by up to 93% and thereby reducing acrylamide formation in baked and fried foods. Field trials over two years showed the edited lines retained normal grain...
Lab Success Doesn't Guarantee Real Cancer Drug Efficacy
Just a reminder. Killing cancer cells in a lab is very easy. Almost anything will kill cells. Even water (because of osmotic damage). Inside our bodies killing cancer cells is extremely hard for many reasons so things that kill...
Could Biotech Layoffs Push Life Sciences Talent to Go Global?
Biotech firms are trimming staff amid a funding slowdown, but the layoffs are prompting a global reshuffling of life‑sciences talent. Major U.S. hubs like Boston see cuts, while the UK, Canada, France, Switzerland and Singapore roll out visa pathways and...
PreVenTB Trial: Considerations for Interpreting Extrapulmonary Tuberculosis Efficacy and Tuberculin Skin Test-Stratified Analyses
The PreVenTB phase‑3 trial evaluated the recombinant BCG vaccine VPM1002 and the subunit vaccine Immuvac in 12,700 Indian household contacts, but neither met the primary endpoint of preventing microbiologically confirmed tuberculosis. The authors noted a 23.1% versus 20.3% six‑month tuberculin...
Drug-Resistant Fungi Prompt a Five-Step Global Plan Ahead of WHO's 2026 Update
An international consortium of 50 researchers led by Radboudumc has issued a five‑step plan to curb the rise of drug‑resistant fungi. The strategy—covering awareness, surveillance, infection control, optimized drug use, and investment—aims to shape the World Health Organization’s 2026 Global...
Off the Shelf Cell Therapies for Bone Marrow Transplantation with Ossium Health’s Kevin Caldwell — Episode 251
In episode 251 of the Xtalks Life Science Podcast, Kevin Caldwell, CEO and co‑founder of Ossium Health, discusses the company’s pioneering off‑the‑shelf bone‑marrow therapy derived from deceased organ donors. The treatment aims to solve long‑standing clinical and logistical hurdles in...
Fear of ‘Vibebioterror’ Overstates Threat, Defends SynBio Education
@strnr do you sincerely think that vibebioterror will be a thing? I honestly think this is fear mongering at its highest caliber. You can go to a community college right now and learn all you need to work with microbes...
RVMD and ALLO Illustrate Biotech's Enduring Success Struggle
Why $RVMD & $ALLO are a microcosm of biotech's historic struggle for success. Some musings from me on @ApexOnco -> https://t.co/3lWgzQplvc
Deep Dive: Checking in with the FDA
The FDA’s 2025 turmoil included a 3,500‑person workforce cut, multiple leadership turnovers, and a surge in guidance reversals that delayed drug reviews. In 2026, the agency declined to file Moderna’s mRNA‑1010 flu vaccine, contradicting earlier guidance, underscoring regulatory uncertainty. Despite...
Advisory Committee Needed to Vet RP1/Replimmune Melanoma Data
I haven’t dug into the specifics of the RP1/Replimmune data in melanoma, but isn’t this an example of where a good old-fashioned Adcomm could help vet the data and overall risk-benefit? https://t.co/qAxtU9pUeF
New Drug Boosts Survival for Platinum‑Resistant Ovarian Cancer
Combining a new drug with #chemotherapy extends the survival of platinum-resistant ovarian #cancer patients in #clinicaltrial https://t.co/JE4r8nISUq
Viewpoint: CRISPR and mRNA — Under Attack by Technology Skeptics — Poised to Save Millions of Children with Rare Diseases
Rare genetic diseases affect roughly 25 million Americans and generate about $400 billion in annual medical costs, yet fewer than five percent have FDA‑approved therapies. The scarcity of treatments stems from the economics of drug development for tiny patient pools. Recent breakthroughs...
Brain Age Gap Predicts Lifestyle Impact on Mental Health
Brain age gap as a predictive biomarker that links aging, lifestyle, and neuropsychiatric health https://t.co/kgvgyZ9v4S
Major Organoids Companies Plus Latest TechBio News
The latest TechBio briefing spotlights the fastest‑growing private organoid firms, highlighting recent Series A‑C rounds that collectively raised over $500 million. Leaders such as OrganoTech, CellSphere, and BioMimic are scaling production pipelines to meet demand from pharma, diagnostics, and personalized‑medicine partners. The...